Group items tagged

Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug. The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165 per cent over the past two years. The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new data could lead the U.S. government to reassess that.

Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for their older, less effective but cheaper, drugs. A weekly injection of Wegovy, which was launched in the U.S. in June 2021, leads to an average weight loss of around 15%, alongside changes to diet and exercise. Its impact has captured the attention of patients, investors and even celebrities. But supply issues for Wegovy manufacturer Novo Nordisk means the Danish drugmaker has struggled to meet surging U.S. demand, delaying a launch in most of Europe. Insurers and some national governments have also baulked at its cost, while a minority of patients do not respond to it. Vivus and Currax Pharmaceuticals, U.S.-based developers whose treatments have been on the U.S. market for around a decade, hope to benefit from the attention and supply shortage. But scientists and investors say that lower efficacy plus side effects could continue to hold the treatments back.

Few if any industries are growing at a quicker and more consistent pace in the U.S. than marijuana. A report released earlier this year by Marijuana Business Daily entitled "Marijuana Business Factbook 2017" found that the U.S. legal-weed market is expected to grow by 45% in 2018, and an aggregate of 300% between 2016 and 2021. If these projections are accurate, we could be talking about a $17 billion market by 2021. With growth like this, it's no wonder why marijuana stocks have gone through the roof in recent years.

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

The first big breakthrough in 30 years of Alzheimer's research is providing momentum for clinical trials of "cocktail" treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai and Biogen reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo. The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer's patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. The U.S. Food and Drug Administration is expected to make a decision by early January on the companies' application for accelerated approval. If approved on an accelerated basis, the companies said they would immediately apply for full U.S. regulatory approval which could help secure Medicare coverage.

Online retail giant Amazon said on Tuesday (January 24) it is offering a $5 monthly subscription plan for U.S. Prime members that will cover a range of generic drugs and their doorstep delivery, furthering the ecommerce giant's push into healthcare. The program, named RxPass, includes more than 50 medications addressing over 80 chronic conditions such as high blood pressure, anxiety, diabetes and male pattern baldness, Vin Gupta, Amazon Pharmacy's chief medical officer, has said. However, customers enrolled in Medicare, Medicaid or any other government healthcare program will not be able to enrol in Amazon Pharmacy's RxPass service. The average Prime member would save about $100 per year with RxPass, John Love, vice president of Amazon Pharmacy, said. Amazon Prime members in most U.S. states can sign up for the program from January 24. The flat $5 charge would be without insurance and on top of the Prime membership fee, which costs $139 per year in the United States.

The U.S. Food & Health Supplement Stores Industry-Industry & Market Report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2013 current and 2014 forecast estimates on the size of the industry (sales, establishments, employment) nationally and for all 50 U.S.

Juvenile arthritis involves 1 in 1,000 children in the U.S.A. The authentications are painfulness; hardness and swelling that last longer than 6 weeks and are not caused by an accidental injury or different sickness. Though the arthritis could initially introduce itself afterward an accidental injury or unwellness these are not the cause.

Somewhere in America, a women is raped every two minutes, according to the U.S. Department of Justice. One in four women are victims of rape or attempted rape, 84% of those women knew their attacker, 57% of the rapes have happened while on dates.

Somewhere in America, a women is raped every two minutes, according to the U.S. Department of Justice. One in four women are victims of rape or attempted rape, 84% of those women knew their attacker, 57% of the rapes have happened while on dates.

Drink Safe Technologies offers you the opportunity to safe guard your own drink by using our Drink Safe Coaster or Test Kit.

If wheat is so bad, what about all the other grains? First of all, I demonize wheat because of its top-of-the-list role in triggering: --Appetite--Wheat increases hunger dramatically --Insulin --Blood sugar--Wheat is worse than table sugar in triggering a rapid, large rise in blood sugar --Triglycerides --Small LDL particles--the number one cause for heart disease in the U.S. --Reduced HDL --Diabetes --Autoimmune diseases--Most notably celiac disease and thyroiditis. Most other "healthy, whole grains" aren't quite as bad. It's a matter of degree.

Can including wheat in your diet create hell on earth? Was The Inferno nothing more than Danté's prediction for the state of the U.S. diet circa 2009? I'm kidding on The Inferno allusion, but the American diet nonetheless sure does create an inferno of unhealthy phenomena.

Vinyl flooring is a popular but relatively inexpensive flooring option in the U.S. You can easily achieve the look of wood, marble, natural stone or tile by using vinyl floors. It's versatile, easy to install and maintain and durable as well.

CP Child Wheelchair Cerebral palsy (CP) is a disorder of the brain. Normally, the brain tells the rest of the body exactly what to do and when to do it.CP affects the brain, a person might not be able to walk, talk, eat, or move the way most people do. CP affects a person's muscle tone and ability to coordinate body movements. People with CP have trouble controlling their muscles. CP affects the part of the brain that controls speech, a person with CP might have trouble talking clearly or not be able to speak at all. Because cerebral palsy affects muscle control, some people have learning disabilities or behavior problems - though many people with CP don't have these issues. Other people with CP also have medical problems like seizures or epilepsy, or hearing impairment. CP may work with these experts: a pediatric orthopedist a developmental pediatrician who looks at how the person is growing or developing compared with other teens a pediatric physiatrist (or rehabilitation physician), who helps kids with disabilities of many kinds therapists, like physical therapists to help with movement, occupational therapists to help with skills like handwriting, and speech therapists Features Ultra light weight aluminum alloy frame Epoxy powder coated frame Detachable arm rest provided Height adjustable and detachable head rest Hydraulic reclining high back for a comfortable posture Detachable back and seat pad Extra cushion upholstery provided to under arm, head. Hand brakes provided Safety belt provided Cerebral Palsy Wheelchair Price Cerebral Palsy is a long-term chronic medical condition that requires long-term supportive care services.Cerebral Palsy often have other associative and co-mitigating medical conditions, including cognitive challenges, vision loss, hearing impairment, and seizures. These conditions require diagnosis, treatment and maintenance all at significant cost.The family of an individual with cerebral palsy is like

Types of CP Associated With Muscle Tone Cerebral palsy comes in several types, which may be associated with muscle tone or specific body parts. Those associated with muscle tone include: spastic CP, where abnormally high muscle tone causes problems with movement, usually in the legs and hips; ataxia, which is marked by involuntary muscle movements; athetoid, which prevents sufferers from maintaining a fixed muscle position (for example, grasping and holding); and mixed, where symptoms of both spastic and athetoid CP occur. Cerebral Palsy: Hope Through Research: Detailed information from the National Institute of Neurological Disorders and Stroke, including facts on the causes, risk factors, warning signs, and types of CP. Definitions and Accommodations for Cerebral Palsy: Information on the types of CP and how to accommodate and interact with severe sufferers. From Kentucky's Office for the Americans With Disabilities Act. United Cerebral Palsy Association: Nonprofit organization that offers a nationwide network of affiliates aimed at expanding the rights, freedoms, and opportunities of those with cerebral palsy. Health Encyclopedia: Cerebral Palsy: Facts on the types, causes, prevalence, and accommodations related to cerebral palsy. Provided by the Florida Agency for Health Care Administration. Cost of Cerebral Palsy: Information on the human and economic impact of cerebral palsy, presented in the form of an academic report composed by the Environmental Protection Agency. Types of CP Associated With Body Parts Certain types of cerebral palsy are associated with specific body parts rather than with the general condition of the muscular system. These types include: quadriplegia, in which all four limbs suffer severe motor dysfunction and a general inability to work together; hemiplegia, in which the limbs on one side of the body are severely affected, with the impact more pronounced in the digits; and diplegia, which causes problems with mus

Dr. Michael Omidi MD, along with his brother Julian Omidi, is cofounder of No More Poverty, an organization promoting the works of charities that strive to end poverty and the conditions that cause poverty both in the U. S. and abroad. In this article, Dr. Michael Omidi discusses the Omidi brothers' sponsorship of Jessica's Hope Project, a foundation that sends healthy care packages to U.S. soldiers overseas.

DRPS Strawberry CBD Full Spectrum Tincture Packed with flavor, Full Spectrum PCR tinctures by Good CBD are a high-quality Phytocannabinoid rich-Distillate. The U.S. grown industrial hemp that we use contains a full spectrum of naturally occurring cannabinoids and terpenes. Our products are formulated using a Phytocannabinoid rich distillate we are able to provide the highest quality PCR extract. Good CBD tinctures may be utilized as a daily herbal supplement. Experience the difference offered by the superior ingredients and techniques that come with Full Spectrum PCR Oil by Good CBD.

Let's take a look at some of the insights found through research that help the policymakers and the system leaders identify the areas that need acute concentration while improving the overall US healthcare system of the country.

Despite significant sales growth in the quarterly results, high street chemist Boots is moving forward with its plan to close 300 stores in the UK. The move, aimed at improving profit margins amid rising costs and competition, will reduce the chain's portfolio from around 2,200 to just 1,900. Last month, the U.S.-based Walgreens Boots Alliance, the parent company of Boots, announced upcoming store closures within the next year. However, the company assured that there will be no job losses as all employees will be given the opportunity to be redeployed to nearby shops. The following sites are confirmed for closure on the specified dates: Heathside Rd, Woking (end of July) UEA campus (end of July) Hamlet Ct Rd, Westcliff-on-Sea (August 1) Windhill Road, Wakefield (October 6) Upper Warrengate, Wakefield (October 7) Glastonbury (October 13) Guildford Road, Woking (end of October) Boots stores at Salford Shopping Centre in Greater Manchester, Church Street in Malvern, The Port Arcades Shopping Centre in Ellesmere, and King William Street in London have already closed since spring.

Capitalising on strong demand for its obesity therapies, Novo Nordisk's growing appetite for deals has fuelled a bet on a U.S. gene-editing company called Life Edit Therapeutics. The Danish drugmaker's collaboration with Durham, North Carolina-based Life Edit Therapeutics - owned by ElevateBio, a cell and gene therapy company in Waltham - is focused on up to seven programs for rare genetic disorders as well as cardiometabolic diseases. At the heart of the tie-up is Life Edit's technology, called base editing, which is designed to make precise changes to the human genome by tweaking one base - or letter - into a different one without affecting other letters. Single-letter mistakes, called point mutations, can give rise to genetic diseases.

Britain plans to launch a pilot programme exploring how new weekly weight-loss shots such as Novo Nordisk's Wegovy can be given to obese patients by general practitioners even as the drug's market launch remains unclear. The government's announcement on the £40 million pilot programme comes after drug cost-effectiveness watchdog NICE in March recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the NHS specialist weight management scheme. The timing of Wegovy's launch in Britain - which would be only the fourth country to use it - is uncertain, however, after Novo last month rationed starter doses to secure supply to U.S. patients already on the regimen, after it was overwhelmed by demand there. British Prime Minister Rishi Sunak said on Wednesday (May 7) the pilot and fighting obesity-related diseases could reduce pressure on hospitals. It would also support "people to live healthier and longer lives, and helping to deliver on my priority to cut NHS waiting lists". The NHS endured a tough winter in England in particular, with waiting lists hitting record highs and staff striking for higher pay amid double-digit inflation.